The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

Authors:

Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP and Mamtani R

Publication type:

Journal article

Publication name:

Journal of Medical Economics

Citation:

Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP and Mamtani R. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. J Med Econ. 2020:1-.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies